Increase of serum lipoprotein (a), an adverse effect of growth hormone treatment

A number of reports show that high endogenous, or therapeutic administration of human growth hormone (hGH) cause an increase of serum lipoprotein a, Lp(a). Being thrombogenic Lp(a) is an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Hence, it is hypothesized that the rec...

Full description

Saved in:
Bibliographic Details
Published in:Growth hormone & IGF research 2022-12, Vol.67, p.101503-101503, Article 101503
Main Author: Laron, Zvi
Format: Article
Language:English
Subjects:
Atherocardiovascular disease
Growth hormone treatment
Lipoprotein(a)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A number of reports show that high endogenous, or therapeutic administration of human growth hormone (hGH) cause an increase of serum lipoprotein a, Lp(a). Being thrombogenic Lp(a) is an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Hence, it is hypothesized that the recently reported association between childhood hGH treatment and cardiovascular morbidity is probably due to the GH effect on Lp(a) synthesis. It is therefore suggested to determine serum Lp(a) levels before and during hGH treatment in children and adults. •Growth Hormone stimulates the synthesis of lipotropin(a) an independent risk factor for atherosclerotic cardiovascular disease.•This so far overseen property of growth hormone may have clinical implications.•Lipotropin(a) should be determined before and during GH treatment
ISSN:1096-6374
1532-2238
DOI:10.1016/j.ghir.2022.101503